8-K/A: Quince Therapeutics: LAM-001 Shows Promise in PAH/PH-ILD Study

Quince Therapeutics announced positive Phase 2a data for LAM-001 in pulmonary hypertension, with a Phase 2b trial planned for mid-2026.

Summary

• Quince Therapeutics released updated Phase 2a data for its investigational drug LAM-001, an inhaled formulation of rapamycin, for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• The study showed clinically meaningful improvements in key measures including six-minute walk distance (6MWD), pulmonary vascular resistance (PVR), and functional class.
• Specifically, the evaluable population (N=6) saw an average 6MWD increase of 81.3 meters and a PVR reduction of 25.5% (exercise) and 28.1% (supine).
• The PH-ILD subgroup (N=4) demonstrated a 67.4-meter increase in 6MWD and a 33.9% reduction in supine PVR.
• All evaluable patients transitioned from Functional Class III to II, with two patients reaching Functional Class I.
• LAM-001 was generally well-tolerated as an add-on therapy to standard of care.
• A Phase 2b trial in PH-ILD is slated to begin in mid-2026, with topline data expected in Q1 2028.
• Additional studies are planned for bronchiolitis obliterans syndrome (BOS) and sarcoidosis-associated pulmonary hypertension (SAPH).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the clinically meaningful improvements shown in a difficult-to-treat patient population, supporting continued development.

Positives

• Clinically meaningful improvements observed across multiple measures of disease burden, including exercise capacity (6MWD), pulmonary hemodynamics (PVR), cardiac stress biomarkers (NT-proBNP), and lung function (FVC).
• Significant improvement in 6MWD by 81.3 meters in the evaluable population and 67.4 meters in the PH-ILD subgroup.
• Reduction in pulmonary vascular resistance (PVR) by 25.5% (exercise) and 28.1% (supine) in the evaluable population, and 33.9% (supine) in the PH-ILD subgroup.
• All patients improved from Functional Class III to II, with two reaching Functional Class I.
• LAM-001 was generally well-tolerated as an add-on therapy.
• Advancement to a Phase 2b trial in PH-ILD is planned for mid-2026.
• Data from the Phase 2a study support continued development of LAM-001.
• The drug is being developed for serious and underserved rare pulmonary diseases.

Negatives

• The Phase 2a study was small (10 patients) and open-label, with only 6 evaluable patients at the 24-week endpoint.
• The reported PVR reduction percentages are based on exercise and supine measurements, which may have different clinical implications.
• The amendment to the 8-K filing indicates a correction to previously reported percentages (-35.3% and -28.1% were corrected to -35.3% and -28.1% respectively, which seems to be a typo in the prompt, but the filing states 'replace 35.3% and 28.1% with -35.3% and -28.1%' which implies a change in sign for PVR values). The prompt's provided filing text states 'replace 35.3% and 28.1% with -35.3% and -28.1%', which is a significant change in sign for PVR values, indicating a potential misstatement in the original filing.
• The original filing was amended to correct specific numerical data points, raising questions about the initial accuracy of reporting.

Risks

• Clinical results may not be indicative of future results, especially in larger populations.
• Potential safety and other complications related to LAM-001.
• Challenges in obtaining and maintaining regulatory approval.
• Competition in the pulmonary hypertension and interstitial lung disease treatment market.
• The ability to successfully expand the development of LAM-001.
• Market acceptance of LAM-001 compared to alternative therapies.
• Risks related to macroeconomic and geopolitical conditions impacting the business.
• Uncertainties and risks described in the company's Annual Report on Form 10-K.

Future Outlook

A Phase 2b trial in PH-ILD is planned to initiate in mid-2026, with topline data anticipated in the first quarter of 2028. A Phase 2 study in BOS is ongoing with data anticipated in Q1 2027. A Phase 2 study in sarcoidosis-associated pulmonary hypertension (SAPH) is planned to initiate in late 2026.

Management Comments

• "What is particularly notable in these early data is the consistency of improvement observed across several important markers of disease burden, including exercise capacity, pulmonary vascular resistance, cardiac stress biomarkers and lung function."
• "Improvements in measures such as 6MWD and PVR are especially encouraging given their clinical relevance in pulmonary hypertension and may suggest broader effects on cardiopulmonary physiology."
• "These findings are encouraging for patients and the broader pulmonary hypertension community and support continued development of LAM-001 in PH-ILD, where meaningful therapeutic advances remain urgently needed."

Industry Context

StockSavvy.ai notes that Quince Therapeutics' announcement positions LAM-001 as a potentially significant disease-modifying therapy in the underserved markets of PAH and PH-ILD. The company's strategic acquisition of LAM-001 and its subsequent advancement into later-stage trials reflect a common strategy in the biotech sector to build a pipeline of targeted therapies for rare diseases.

Comparison to Industry Standards

• The reported 6MWD improvement of 67.4 meters in the PH-ILD subgroup is considered clinically meaningful in pulmonary hypertension trials, often exceeding the minimal clinically important difference.
• The PVR reduction of 33.9% in the PH-ILD subgroup is substantial and aligns with positive outcomes seen with other advanced therapies in pulmonary hypertension, though direct comparisons are limited due to study design differences.
• The transition of all evaluable patients from Functional Class III to II is a strong positive indicator, as functional class improvement is a key regulatory endpoint.
• The overall safety profile appears favorable, which is critical for add-on therapies in a patient population already on standard of care.

Stakeholder Impact

• Shareholders: Potential for increased company valuation if LAM-001 successfully navigates further clinical development and regulatory approval.
• Patients with PAH and PH-ILD: Potential for a new, disease-modifying treatment option that offers clinically meaningful improvements in symptoms and disease progression.
• Healthcare Providers: Provides a new therapeutic avenue for managing complex pulmonary hypertension cases.
• Competitors: Highlights the ongoing innovation in the pulmonary hypertension space and may influence their R&D strategies.

Next Steps

• Initiate Phase 2b trial in PH-ILD in mid-2026.
• Anticipate topline data from Phase 2b PH-ILD trial in Q1 2028.
• Initiate Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH) in late 2026.
• Present data from ongoing Phase 2 study in bronchiolitis obliterans syndrome (BOS) in Q1 2027.

Key Dates

Recommendation

The Phase 2a data are encouraging and support continued development, but the drug is still in early-stage trials with significant hurdles ahead, including Phase 2b and Phase 3 studies, regulatory approval, and market competition. Therefore, a 'hold' recommendation is appropriate pending further de-risking events.

Keywords

LAM-001, Quince Therapeutics, Pulmonary Hypertension, PH-ILD, PAH, Rapamycin, Clinical Trial, Biotechnology